The identification of seven distinct GLA gene mutations in a cohort of 409 cardiomyopathy patients, yielding an approximate prevalence of 3.4%, suggests that a substantial number of FD cases within cardiac populations may remain undiagnosed through conventional clinical pathways or broader screening efforts. This evidence concerns the gene GLA and Fabry disease.